256 related articles for article (PubMed ID: 27688473)
1. Repeatability of
Lodge MA; Holdhoff M; Leal JP; Bag AK; Nabors LB; Mintz A; Lesser GJ; Mankoff DA; Desai AS; Mountz JM; Lieberman FS; Fisher JD; Desideri S; Ye X; Grossman SA; Schiff D; Wahl RL
J Nucl Med; 2017 Mar; 58(3):393-398. PubMed ID: 27688473
[TBL] [Abstract][Full Text] [Related]
2. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
[TBL] [Abstract][Full Text] [Related]
3. Repeatability of quantitative
Kramer GM; Liu Y; de Langen AJ; Jansma EP; Trigonis I; Asselin MC; Jackson A; Kenny L; Aboagye EO; Hoekstra OS; Boellaard R;
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):951-961. PubMed ID: 29362858
[TBL] [Abstract][Full Text] [Related]
4. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
[TBL] [Abstract][Full Text] [Related]
5. 3'-Deoxy-3'-18F-fluorothymidine PET-derived proliferative volume predicts overall survival in high-grade glioma patients.
Idema AJ; Hoffmann AL; Boogaarts HD; Troost EG; Wesseling P; Heerschap A; van der Graaf WT; Grotenhuis JA; Oyen WJ
J Nucl Med; 2012 Dec; 53(12):1904-10. PubMed ID: 23077112
[TBL] [Abstract][Full Text] [Related]
6. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
[TBL] [Abstract][Full Text] [Related]
7. Kinetics of 3'-deoxy-3'-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma.
Schiepers C; Dahlbom M; Chen W; Cloughesy T; Czernin J; Phelps ME; Huang SC
J Nucl Med; 2010 May; 51(5):720-7. PubMed ID: 20395318
[TBL] [Abstract][Full Text] [Related]
8. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors.
Jacobs AH; Thomas A; Kracht LW; Li H; Dittmar C; Garlip G; Galldiks N; Klein JC; Sobesky J; Hilker R; Vollmar S; Herholz K; Wienhard K; Heiss WD
J Nucl Med; 2005 Dec; 46(12):1948-58. PubMed ID: 16330557
[TBL] [Abstract][Full Text] [Related]
9. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine.
Eckel F; Herrmann K; Schmidt S; Hillerer C; Wieder HA; Krause BJ; Schuster T; Langer R; Wester HJ; Schmid RM; Schwaiger M; Buck AK
J Nucl Med; 2009 Sep; 50(9):1441-7. PubMed ID: 19690030
[TBL] [Abstract][Full Text] [Related]
10. Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma.
Ullrich R; Backes H; Li H; Kracht L; Miletic H; Kesper K; Neumaier B; Heiss WD; Wienhard K; Jacobs AH
Clin Cancer Res; 2008 Apr; 14(7):2049-55. PubMed ID: 18381944
[TBL] [Abstract][Full Text] [Related]
11. Dynamic small-animal PET imaging of tumor proliferation with 3'-deoxy-3'-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas.
Bradbury MS; Hambardzumyan D; Zanzonico PB; Schwartz J; Cai S; Burnazi EM; Longo V; Larson SM; Holland EC
J Nucl Med; 2008 Mar; 49(3):422-9. PubMed ID: 18287265
[TBL] [Abstract][Full Text] [Related]
12. Repeatability of 18F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials.
Weber WA; Gatsonis CA; Mozley PD; Hanna LG; Shields AF; Aberle DR; Govindan R; Torigian DA; Karp JS; Yu JQ; Subramaniam RM; Halvorsen RA; Siegel BA; ;
J Nucl Med; 2015 Aug; 56(8):1137-43. PubMed ID: 25908829
[TBL] [Abstract][Full Text] [Related]
13. Imaging regional variation of cellular proliferation in gliomas using 3'-deoxy-3'-[18F]fluorothymidine positron-emission tomography: an image-guided biopsy study.
Price SJ; Fryer TD; Cleij MC; Dean AF; Joseph J; Salvador R; Wang DD; Hutchinson PJ; Clark JC; Burnet NG; Pickard JD; Aigbirhio FI; Gillard JH
Clin Radiol; 2009 Jan; 64(1):52-63. PubMed ID: 19070698
[TBL] [Abstract][Full Text] [Related]
14. 11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma.
Hatakeyama T; Kawai N; Nishiyama Y; Yamamoto Y; Sasakawa Y; Ichikawa T; Tamiya T
Eur J Nucl Med Mol Imaging; 2008 Nov; 35(11):2009-17. PubMed ID: 18542957
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of 3'-deoxy-3'-18F-fluorothymidine ([(18)F] FLT PET) in patients with recurrent malignant gliomas.
Zhao F; Cui Y; Li M; Fu Z; Chen Z; Kong L; Yang G; Yu J
Nucl Med Biol; 2014 Sep; 41(8):710-5. PubMed ID: 24929963
[TBL] [Abstract][Full Text] [Related]
16. Comparison of 3'-deoxy-3'-[18F]fluorothymidine PET and O-(2-[18F]fluoroethyl)-L-tyrosine PET in patients with newly diagnosed glioma.
Jeong SY; Lim SM
Nucl Med Biol; 2012 Oct; 39(7):977-81. PubMed ID: 22483845
[TBL] [Abstract][Full Text] [Related]
17. Comparison of 18F-fluorodeoxyglucose and 18F-fluorothymidine PET in differentiating radiation necrosis from recurrent glioma.
Enslow MS; Zollinger LV; Morton KA; Butterfield RI; Kadrmas DJ; Christian PE; Boucher KM; Heilbrun ME; Jensen RL; Hoffman JM
Clin Nucl Med; 2012 Sep; 37(9):854-61. PubMed ID: 22889774
[TBL] [Abstract][Full Text] [Related]
18. Reproducibility of 3'-deoxy-3'-(18)F-fluorothymidine microPET studies in tumor xenografts in mice.
Tseng JR; Dandekar M; Subbarayan M; Cheng Z; Park JM; Louie S; Gambhir SS
J Nucl Med; 2005 Nov; 46(11):1851-7. PubMed ID: 16269599
[TBL] [Abstract][Full Text] [Related]
19. Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity.
Troost EG; Bussink J; Slootweg PJ; Peeters WJ; Merkx MA; van der Kogel AJ; Oyen WJ; Kaanders JH
J Nucl Med; 2010 May; 51(5):713-9. PubMed ID: 20395329
[TBL] [Abstract][Full Text] [Related]
20. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas.
Fueger BJ; Czernin J; Cloughesy T; Silverman DH; Geist CL; Walter MA; Schiepers C; Nghiemphu P; Lai A; Phelps ME; Chen W
J Nucl Med; 2010 Oct; 51(10):1532-8. PubMed ID: 20847166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]